Bottom line:$13 million cash now on the balance sheet.
14% revenue growth vs. the same 9 months period last year.
$19.075 million revenue over the last 4 quarters.
On track to meet guidance yet again with another year of double digit revenue growth consistent with revenue growth the last 10 years.
With Q4 not reported for another 5 months and Q1 to follow one month later the focus can now turn to the avenanthramide trial, fibrosis, and PGX, etc. Approval for the avenanthramide trial should be imminent.